Sermorelin alternatives.
10 compounds compared to Sermorelin, ranked by published evidence tier and regulatory status, not by what's marketed hardest.
Sermorelin is a strange case, because it was approved and then simply stopped being sold. Geref and Geref Diagnostic held FDA approval for testing pituitary GH reserve and for idiopathic GH deficiency in children, and were voluntarily withdrawn from the US market in 2008 for commercial reasons rather than any safety or efficacy failure. Today there is no FDA-approved finished product and US access is through compounded preparations, which is what sends people looking. Within the GHRH analog family, tesamorelin is the one that still holds an approval, though for a narrow indication. The research-market analogs built on the same GHRH(1-29) backbone hold none.
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary to release growth hormone (GH).
- 01TesamorelinA tierFDA-approvedEgrifta
Acts through the ghrh signalling pathway, like Sermorelin. FDA-approved.
- 02CJC-1295F tierResearch / preclinical
Acts through the ghrh signalling pathway, like Sermorelin. Research / preclinical.
- 03CJC-1295 DACF tierResearch / preclinical
Acts through the ghrh signalling pathway, like Sermorelin. Research / preclinical.
- 04Mod-GRF (1-29)F tierResearch / preclinicalCJC-1295 no-DAC
Acts through the ghrh signalling pathway, like Sermorelin. Research / preclinical.
- 05
- 06
- 07GHRP-1D tierResearch / preclinicalgrowth hormone-releasing peptide-1
Same category: growth hormone. Research / preclinical.
- 08GHRP-2D tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 09GHRP-6D tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
- 10HexarelinD tierResearch / preclinical
Same category: growth hormone. Research / preclinical.
An “alternative” here means a compound that shares Sermorelin's mechanism pathway or sits in the same category, not a marketing substitute. Each is ordered by PepCue's evidence tier (a weighted 0–100 score across human data, safety, replication and regulatory clarity), then by whether it's actually approved. This is a research reference, not medical or purchasing advice: an alternative sitting higher on evidence does not mean it's right, safe, or legal for any given use. Reviewed June 1, 2026.
PepCue keeps every compound, dose and lab in one private, provider-ready timeline, whichever one you land on.